Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies

Journal of Managed Care Pharmacy

Volumn 13, Issue 7, 2007, Pages 561-569

  Wu, Eric Q ^a   Birnbaum, Howard G ^a   Ivanova, Jasmina I ^a   Yang, Elaine ^a   Zhang, Huabin F ^b   Mallet, David ^c  

^a ANALYSIS GROUP   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Ingenix Inc   (United States)

Author keywords

ADHD; Atomoxetine; Attention deficit hyperactivity disorder; Costs; Extended release methylphenidate; MAS XR; Mixed amphetamine salts; OROS MPH

Indexed keywords

AMPHETAMINE; ATOMOXETINE; METHYLPHENIDATE;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BILLING AND CLAIMS; COMORBIDITY; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DEMOGRAPHY; DEPRESSION; DISEASE CLASSIFICATION; DRUG CLASSIFICATION; DRUG COST; DRUG RELEASE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE PERSONNEL; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; INSURANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; OUTPATIENT; RISK ASSESSMENT; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; STUDENT T TEST; SUBSTANCE ABUSE;

EID: 35349026261     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.7.561     Document Type: Article

References (39)

1. Kessler RC, Adler L, Ames M, et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med. 2005;47(6):565-72.
2. Doyle R. The history of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):203-14.
3. McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry. 2004;161:1948-56.
4. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):187-201.
5. Biederman J. Impact of comorbidity in adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2004;65(S3):3-7.
6. Weiss MD, Weiss JR. A guide to the treatment of adults with ADHD. J Clin Psychiatry. 2004;65(S3):27-37.
7. Wilens TE, Dodson W. A clinical perspective of attention-deficit/ hyperactivity disorder into adulthood. J Clin Psychiatry. 2004;65(10):1301-13.
8. Spencer TJ, Biederman J, Wilens T. Stimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):361-72.
9. Secnik K, Swensen A, Lage MJ. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder. Pharmacoeconomics. 2005;23(1):93-102.
10. Swensen A, Birnbaum HG, Ben Hamadi R, Greenberg P, Cremieux P-Y, Secnik K. Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health. 2004;35(2):346e1-e9.
11. Birnbaum HG, Kessler RC, Lowe SW, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin. 2005;21(2):195-206.
12. Swensen A, Birnbaum HG, Secnik K, et al. Attention-deficit/hyperactivity disorder (ADHD): increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry. 2003;42(12):1415-23.
13. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord. 2002; 5:189-202.
14. Safren SA, Sprich S, Chulvic S, Otto MW. Psychosocial treatments for adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):349-60.
15. Spencer TJ. ADHD treatment across the life cycle. J Clin Psychiatry. 2004;65(suppl 3):22-26.
16. Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2005;44(10):1015-23.
17. Christman AK, Fermo JD, Markowitz JS. Atomoxetine, a novel treatment for attention-deficit/hyperactivity disorder. Pharmacotherapy. 2004;24(8):1020-36.
18. Stein MA. Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments. Am J Manag Care. 2004;10:S89-S98.
19. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(2 suppl):26S-49S.
20. Little R, Rubin D. Statistical Analysis with Missing Data. New York: John Wiley & Sons; 1987:62-67.
21. Wedderburn RWM. Quasi-likelihood functions, generalized linear models, and the Gauss-Newton method. Biometrika. 1974;61:439-47.
22. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20:461-94.
23. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17:283-95.
24. Perwien A, Hall J, Swensen A, Swindle R. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/ hyperactivity disorder. J Manag Care Pharm. 2004;10(2):122-29. Available at: http://www.amcp.org/data/jmcp/Research-122-129.pdf.
25. Van Brunt DL, Johnston JA, Ye W, Pohl GM, O'Hara NN. Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data. J Manag Care Pharm. 2006;12(3):230-38. Available at: http://www.amcp.org/data/jmcp/ Research_230-238.pdf.
26. Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373-83.
27. Romano PS, Roos LL, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol. 1993;46(10):1075-79.
28. Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Alloc. 2005;9:3-5.
29. Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf. 2001;10:85-94
30. Lord J, Paisley S. The Clinical Effectiveness and Cost-Effectiveness of Methylphenidate for Hyperactivity in Childhood, Version 2. London, England: National Institute for Clinical Excellence; 2000.
31. Zupancic JAF, Miller A, Raina P, Lee SK, Klassen A, Olsen L. Part 3: Economic evaluation of pharmaceutical and psychological/behavioural therapies for attention-deficit/hyperactivity disorder. In: Miller A, Lee SK, Raina P, et al., eds. A Review of Therapies for Attention-Deficit/Hyperactivity Disorder. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment; 1998.
32. Marchetti A, Magar R, Lau H, et al. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther. 2001;23(11):1904-21.
33. Sankaranarayanan J, Puumala SE, Kratochvil CJ. Diagnosis and treatment of adult attention-deficit/hyperactivity disorder at US ambulatory care visits from 1996 to 2003. Curr Med Res Opin. 2006;22(8):1475-91.
34. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27.
35. Averill RF, Goldfield N, Hughes JS, et al. All patient refined diagnosis related groups (APR-DRGs). Version 20.0. Methodology overview. Available at: http://www.hcup-us.ahrq.gov/db/nation/nis/APR- DRGsV20MethodologyOverviewandBibliography.pdf. Accessed April 6, 2007.
36. Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res. 2003;38(4):1103-20.
37. Yan Y, Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Comorbidity indices to predict mortality from Medicare data: results from the national registry of atrial fibrillation. Med Care. 2005;43(11):1073-77.
38. ICD9data.com - free ICD-9-CM database. Available at: http://www.icd9data. com/2007/Volume1/290-319/300-316/314/default.htm. Accessed June 27, 2007.
39. Nissenson AR, Wade S, Goodnough T, Knight K, Dubois RW. Economic burden of anemia in an insured population. J Manag Care Pharm. 2005; 11(7):565-74. Available at: http://www.amcp.org/data/jmcp/ Original%20Research_565_574.pdf.